Note: After January 21, 2020, all press releases are published in English as original language.

ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important…

Read more

ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept

Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively…

Read more

ExpreS2ion appoints new Chief Medical Officer

Hørsholm, Denmark, December 21, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces the appointment of Dr. Mattis F. Ranthe as the Company’s new Chief Medical Officer (CMO). Dr. Ranthe brings a decade of broad clinical experience, and he will be responsible for ensuring the progression of ExpreS2ion’s development pipeline activities, including…

Read more

Pareto Securities and Analysguiden publish research reports; Pareto increases price target to SEK 79

Hørsholm, Denmark, December 9, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in December, following the publication of initial results for the phase II testing of ABNCoV2. Pareto reiterated its ‘buy’ rating and increased its target price SEK…

Read more

Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine

Hørsholm, Denmark, December 5, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. The existing levels of SARS-CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious…

Read more

ExpreS2ion will participate in key investor events in December 2021

Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.

Read more

Pareto Securities and Analysguiden publish research reports; Analysguiden increases price target to SEK 60

Hørsholm, Denmark, November 19, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in November, following the publication of Q3 2021 results. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has…

Read more

ExpreS2ion announces financial results for the third quarter of 2021

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion’s Interim Report for Q3 2021 will be published today

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Interim Report for Q3 2021 will be published today, as the report is finalized earlier than planned. The previous date for publication of the report was Thursday, November 18[th], 2021.

Read more

Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results

Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met…

Read more

ExpreS2ion will participate in key investor and industry events in October 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor and industry events in October. These include events hosted by HC Andersen Capital as well as the World Vaccine Congress and BIO-EUROPE.

Read more

Warrants of series TO5 were subscribed to approximately 97.4 percent and ExpreS2ion receives approximately SEK 44.3 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SINGAPORE, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…

Read more

Last day of trading in warrants of series TO5 is September 16, 2021

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion announces TO5 warrant exercise price and start of subscription period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion will participate in key investor events in September 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in September. These include events hosted by LSX Leaders, Aktiespararna, Økonomisk Ugebrev and Dansk Aktionærforening.

Read more

Pareto Securities and Analysguiden publish research reports with increased price targets of SEK 68 and SEK 55, respectively

Hørsholm, Denmark, August 25, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK…

Read more

The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic, the exclusive licensee of the ABNCoV2 COVID-19 vaccine, will receive up to DKK 800 million in funding from the Danish Ministry of Health for a Phase III trial to confirm safety and demonstrate efficacy as a…

Read more

ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

COVID-19 Phase II clinical trial initiated to evaluate ABNCoV2 as a booster vaccine

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a Phase II clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic. The trial will investigate the potential of ABNCoV2 as a booster vaccine for individuals with previous…

Read more

Correction: ExpreS2ion announces financial results for the second quarter of 2021

Hørsholm, Denmark, August 19, 2021 – This morning ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announced its second quarter financial results for 2021. Some figures were reported incorrectly, specifically the operating income and H1 2020 earnings per share figures reported below in the press release, which are now highlighted in bold. These figures were also incorrect on…

Read more

ExpreS2ion announces financial results for the second quarter of 2021

Hørsholm, Denmark, August 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q2 2021 interim report via webcast on Thursday, August 19, 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its second quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on August 19[th], 2021, at 11-11.30hrs.

Read more

Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine

Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that COUGH-1, the COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine, as headline results has met its safety and efficacy endpoints with excellent virus neutralization levels of up to 12 times higher compared to the levels achieved…

Read more

Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine

Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that University of Oxford has initiated the VAC080-study, a Phase Ib clinical trial to assess the safety and immunogenicity of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/Matrix-M in adults and infants living in Tanzania.

Read more

ExpreS2ion publishes video from company presentation at a Nordic investor event

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the LifeSci Advisors Nordic Biotech Summit investor event on June 29, 2021 is now available on the company’s Vimeo channel.

Read more

Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share

Hørsholm, Denmark, June 24, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS2ion. They initate coverage with a Buy rating and a target price of 60 SEK per share.

Read more

ExpreS2ion will participate in key investor events in June 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in June, all of which will be held digitally. These include HC Andersen Capital’s Life Science Seminar (June 16), and LifeSci Advisors Nordic Biotech Summit (June 29).

Read more

Announcement from ExpreS2ion's annual general meeting

The annual general meeting 2021 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 26 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, the AGM was carried out through postal voting only, without physical presence.

Read more

ExpreS2ion Announces Financial Results for the First Quarter of 2021

Hørsholm, Denmark, May 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q1 2021 interim report via webcast on Wednesday, May 19, 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its first quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on May 19th, 2021, at 12-12.30hrs.

Read more

Lead candidate selected in ExpreS2ion’s HER2-cVLP breast cancer vaccine project

Hørsholm, Denmark, May 11, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.

Read more

ExpreS2ion - Annual report for 2020 published

Hørsholm, Denmark, May 05, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2020 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

Read more

Warrants of series TO4 were subscribed to approximately 97.6 percent and ExpreS2ion receives approximately SEK 39.0 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Hørsholm,…

Read more

ExpreS2ion appoints new Vice President, Business Development

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Eske Rygaard-Hjalsted as new Vice President, Business Development. Mr. Rygaard-Hjalsted brings more than 25 years of sales, marketing, and business development experience and will be focused on growing the Company’s commercial foothold, both with…

Read more

Proposal for election of two new members of the Board of Directors

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Gitte L. Pedersen does not seek re-election to the Board of Directors at the forthcoming Annual General Meeting on May 26, 2021, and that two new members, Karin Garre and Sara Sande, are proposed for election. Thus, it is proposed to…

Read more

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 26 May 2021.

Read more

Analysguiden announces new research report with the target price for ExpreS2ion increased to 49 SEK per share

Hørsholm, Denmark, April 22, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case increases to 49 SEK per share.

Read more

Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine

Hørsholm, Denmark, April 21, 2021 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Med. The article highlights the outcome of the VAC063-study, a Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate…

Read more

Last day of trading in warrants of series T04 is April 22, 2021

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in…

Read more

ExpreS2ion announces T04 warrant exercise price, start of subscription period and Board and Executive Management commitment to fully exercise their T04 warrant holdings

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Viruses. The article describes the site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.

Read more

ExpreS2ion updates on its pipeline outlook, including for COVID-19 and HER2 breast cancer projects

Hørsholm, Denmark, March 16, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today presents an updated outlook for its pipeline development projects, including the ABNCoV2 COVID-19 vaccine and its ES2B-C001 HER2-cVLP breast cancer vaccine. The update is published ahead of a digital company presentation to be held today at 11.00 CET, during…

Read more

Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Hørsholm, Denmark, March 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The…

Read more

ExpreS2ion will participate at key industry and investor events in March 2021

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna’s Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).

Read more

ExpreS2ion Announces 2020 Fourth Quarter and Full-Year Results

Hørsholm, Denmark, February 25, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its full-year financial results for 2020 and the fourth quarter of 2020. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the…

Read more

ExpreS2ion’s CEO in interview on achievements in 2020 and the company’s outlook for 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with the company’s CEO Bent Frandsen, in which he sums up the company’s achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.

Read more

ExpreS2ion granted exclusive global license for HER2-cVLP breast cancer vaccine programme from AdaptVac

Hørsholm, Denmark, February 2, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the company has today exercised its option to license a unique breast cancer vaccine by signing a final Patent License Agreement (“the Agreement”) with AdaptVac ApS (“AdaptVac”). ExpreS2ion is granted an exclusive global license to a preclinical-stage novel…

Read more

Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.

Read more